In a meta-analysis of 4500 AML patients by Shivarov et al., DNMT3A mutations showed a significantly worse prognosis, particularly in patients with cytogenetically normal AML (CN-AML) [29]. The gene discussed is DNMT3A; the disease is acute myeloid leukemia.